Drug Profile
Research programme: anti-L1 monoclonal antibodies - MediGene/German Cancer Research Center
Latest Information Update: 30 Aug 2010
Price :
$50
*
At a glance
- Originator German Cancer Research Center
- Developer Celltrion; MediGene AG
- Class Monoclonal antibodies
- Mechanism of Action Cell adhesion molecule inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 17 Jul 2008 MediGene and Celltrion agree to co-promote and co-develop the products in Asia for Cancer
- 17 Jul 2008 Products licensed to Medigene worldwide for the treatment of Cancer
- 12 Mar 2008 Preclinical development for cancer is ongoing